

INTERNAL MEDICINE ALERT

A twice-monthly update of developments in internal and family medicine

Providing Evidence-based
Clinical Information for 30 Years

AHC Media LLC Home Page—www.ahcmedia.com

CME for Physicians—www.cmeweb.com

AHC Media LLC

INSIDE

The new face
of hepatitis A
page 187

Treating
sexual
dysfunction
related to
use of anti-
depressants
page 188

'Weekend
effect' and
stroke
page 191

Financial Disclosure:
Internal Medicine Alert's editor, Stephen Brunton, MD, is a consultant for Amylin, Novo Nordisk, Shionogi Pharma, Takeda, and Teva; he serves on the speakers bureau of Boehringer Ingelheim, Novo Nordisk, and Teva. Peer reviewer Gerald Roberts, MD, reports no financial relationship to this field of study.

Who Knew? You Can Be Too Thin! Of Course, Most People Aren't...

ABSTRACT & COMMENTARY

By Barbara A. Phillips, MD, MSPH

Professor of Medicine, University of Kentucky;
Director, Sleep Disorders Center, Samaritan Hospital, Lexington

Dr. Phillips is a consultant for Cephalon, and serves
on the speaker's bureaus for Resmed and Respiroics.

Synopsis: In a large study of American adults, all-cause mortality was lowest for those with a body mass index (BMI) of 20.0-24.9 kg/m².

Source: Berrington de Gonzalez AB, et al. Body-mass index and mortality among 1.46 million white adults. *N Engl J Med* 2010;363:2211-2219.

THIS REPORT RESULTS FROM A POOLED ANALYSIS OF 1.46 MILLION WHITE adults who were enrolled in 19 different prospective studies funded by the National Cancer Institute. To be included in this analysis, a study had to have started in 1970 or later, and had to include data about height, weight, and smoking status. Most studies also included information about pre-existing health conditions, alcohol consumption, cardiac disease, education, marital status, and physical activity. The investigators formatted these variables to be consistently classified across studies into standard categories. The cause of death was determined from death certificates or medical records. Analyses used proportional-hazards models, with age as the underlying time variable, and adjusted for alcohol intake, educational level, marital status, and physical activity. These investigators defined a BMI of 22.5-24.9 kg/m² as the referent category because of previous studies demonstrating this BMI was usually associated with the lowest mortality.

In the large, combined (1.46 million people) cohort, 58% were women, median age was 58 years, and median BMI was 26.2 kg/m². Smoking was inversely correlated with BMI; only 13% of the cohort were active smokers, though only 53% reported that they had

EDITOR
Stephen A. Brunton, MD
Adjunct Clinical Professor
University of North Carolina,
Chapel Hill

ASSOCIATE EDITORS
James Chan, PharmD, PhD
Pharmacy Quality and
Outcomes Manager, Kaiser
Permanente, Oakland, CA

William T. Elliott, MD, FACP
Chair, Formulary Committee,
Northern California Kaiser
Permanente; Assistant Clinical
Professor of Medicine, University of
California, San Francisco

Mary Elina Ferris, MD
Clinical Associate Professor, Uni-
versity of Southern California

Ken Grauer, MD
Professor, Assistant Director, Fam-
ily Practice Residency
Program, University of Florida

Rahul Gupta, MD, MPH, FACP
Clinical Assistant Professor,
West Virginia University
School of Medicine
Charleston, WV

Harold L. Karpman, MD,
FACC, FACP
Clinical Professor of Medicine,
UCLA School of Medicine

Louis Kuritzky, MD
Clinical Assistant Professor,
University of Florida,
Gainesville

Barbara A. Phillips, MD, MSPH
Professor of Medicine,
University of Kentucky;
Director, Sleep Disorders
Center, Samaritan Hospital,
Lexington

Joseph E. Scherger, MD, MPH
Clinical Professor, University of
California, San Diego

Joseph Varon, MD, FACP,
FCCP, FCCM
Clinical Professor of Medicine and
Professor of Acute and Continuing
Care, University of Texas Health
Science Center, Houston; Clinical
Professor of Medicine, University
Texas Medical Branch, Galveston

Eileen C. West, MD
Director, Primary Care Women's
Health, Clinical Assistant Profes-
sor, Internal Medicine/Obstetrics
and Gynecology; University of
Oklahoma Health Sciences
Center, Oklahoma City

Allan J. Wilke, MD, MA
Chair, Department of Integrative
Medicine, Ross University
School of Medicine
Commonwealth of Dominica

PEER REVIEWER
Gerald Roberts, MD
Assistant Clinical Professor of
Medicine, Albert Einstein College of
Medicine, New York, NY

VOLUME 32 • NUMBER 24 • DECEMBER 29, 2010 • PAGES 185-192

INTERNAL MEDICINE ALERT IS AVAILABLE ONLINE
www.internalmedicinealert.com

never smoked. Pre-existing cancer and emphysema were more common in thinner people, but physical inactivity and lack of a college degree were both associated with a higher BMI.

The rate of death from any cause was lowest among those with a BMI of 22.5-24.9 kg/m², and the risk of death increased with both higher and lower levels of BMI. When the investigators excluded smokers and those with heart disease or cancer at baseline, the risk of death increased for a BMI > 25 kg/m², but decreased for a BMI < 22.5 kg/m². The hazard ratios by BMI for death for healthy women who never smoked are presented in Table 1 (right); results were similar for men.

Further adjustment for alcohol consumption, physical activity, educational level, and marital status only slightly reduced the hazard-ratio estimates associated with a BMI ≥ 25 kg/m². The risk of a higher BMI was greater for younger people. The cause of death for a BMI ≥ 25 kg/m² was highest for heart disease and lowest for cancer.

The risk of death for those with lower (< 20 kg/m²) BMIs declined as the length of follow-up increased, and was only significant for the very thinnest people (BMI < 18.4 kg/m²) at 15 or more years of follow-up.

■ COMMENTARY

This is not the first paper to show a relationship between obesity and death, of course, but it is the largest. Further, the authors were able to adjust for smoking and prevalent illness, which has not always been possible in many prior studies of the relationship between BMI and

Table 1. Hazard ratios by BMI for death in healthy women who never smoked.

BMI (kg/m ²)	Risk Hazard Ratio for Death
25-29.9	1.13
30-34.9	1.44
35-39.9	1.88
40-49.9	2.51

mortality.¹⁻⁴ The current study also confirms that being “merely” overweight (defined as a BMI between 25 kg/m² and 30 kg/m²) is associated with an increased risk of death.^{1,4,5} The authors note that although the data suggest that very thin people have increased risk of death in the short run, this risk is weak in the long run, and the association between low BMI and death was much weaker in physically active people. They interpret this to mean that the association between low BMI and death probably results from pre-existing disease.

The relevance of these findings is amplified by the fact that they apply to so many people. Two-thirds of United States adults are overweight or obese.^{6,7} Among non-Hispanic persons in the United States, an estimated 11% of men and 17% of women had a BMI ≥ 35 in 2008.⁷

Sadly, there were more than five times as many deaths among participants in the highest BMI categories (BMI of 35.0-39.9 kg/m² and 40.0-49.9 kg/m²) than in previous related studies,¹⁻⁵ because severe obesity has become more common.

Let’s face it: Obesity and overweight are huge medical problems in this country. American ingenuity has responded in predictable ways. Weight Watchers is a \$1.4 billion industry, with a vast array of options for the would-be thin person, including books, internet programs, special food products, and branded items on menus of some popular restaurant chains.⁸ Just in time for the holidays, the highly successful Weight Watchers program just announced a new point system. And Weight Watchers works.⁹ Of course, most insurance plans won’t pay for Weight Watchers. They will, however, often pay for bariatric gastric reduction procedures — one of which has just been recommended by an FDA panel¹⁰ to be approved for use in those who have a BMI of just 30 kg/m² — along with a medical complication. Is there something wrong with this picture?

For those of us on the front lines, the message is clear: Painful and time-consuming as it is, we must deliver the message that being overweight or obese kills. Since most of my patients have sleep apnea (and diabetes and hypertension), I have a great deal of experience with this endeavor. And most of it is pretty negative. Patients expect the doctor to tell them to quit smoking. But they

Internal Medicine Alert, ISSN 0195-315X, is published monthly by AHC Media LLC, 3525 Piedmont Rd., NE, Bldg. 6, Suite 400, Atlanta, GA 30305.

EXECUTIVE EDITOR: Coles McKagen.
SENIOR MANAGING EDITOR: Paula Cousins.

GST Registration Number: R128870672.

Periodicals Postage Paid at Atlanta, GA 30304 and at additional mailing offices.

POSTMASTER: SEND ADDRESS CHANGES TO *Internal Medicine Alert*, P.O. Box 740059, ATLANTA, GA 30374.

Copyright © 2010 by AHC Media LLC. All rights reserved. No part of this newsletter may be reproduced in any form or incorporated into any information-retrieval system without the written permission of the copyright owner.

Back issues: \$21. Missing issues will be fulfilled by customer service free of charge when contacted within one month of the missing issue’s date.

This is an educational publication designed to present scientific information and opinion to health professionals, to stimulate thought, and further investigation. It does not provide advice regarding medical diagnosis or treatment for any individual case. It is not intended for use by the layman.



Subscriber Information

Customer Service: 1-800-688-2421.

Customer Service E-Mail: customerservice@ahcmmedia.com

Editorial E-Mail: paula.cousins@ahcmmedia.com

World-Wide Web: www.ahcmmedia.com

Subscription Prices

United States

1 year with free AMA Category 1 credits: \$319

Add \$17.95 for shipping & handling.

(Student/Resident rate: \$125)

Multiple Copies

Discounts are available for group subscriptions, multiple copies, site-licenses or electronic distribution. For pricing information, call Tria Kreutzer at 404-262-5482.

Canada

Add 7% GST and \$30 shipping.

Elsewhere

Add \$30 shipping.

Accreditation

AHC Media LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AHC designates this educational activity for a maximum of 45 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Internal Medicine Alert has been reviewed and is acceptable for up to 24 Prescribed credits by the American Academy of Family Physicians. AAFP accreditation begins 01/01/07. Term of approval is for one year from this date. Each issue is approved for 1 Prescribed credit. Credit may be claimed for 1 year from the date of each issue. The AAFP invites comments on any activity that has been approved for AAFP CME credit. Please forward your comments on the quality of this activity to oncomment@aafp.org.

This CME activity is intended for the internist/family physician. It is in effect for 36 months from the date of the publication.

Questions & Comments

Please call Paula Cousins, Senior Managing Editor, at (404) 262-5488.

Table 2. Items that contain about 250 calories.

2 1/2 apples
5 strips of bacon
20 oz of beer (1 3/4 cans)
10 carrots
1/6 quart ice cream
1/2 cheeseburger
10 oranges
5 chocolate chip cookies
20 oz of cola beverage (1 3/4 cans)
3 glasses of skim milk
2 1/2 fried eggs
1 fried chicken breast

Table 3. Activities that consume about 250 calories for a 150-lb person (more for a heavier person).

Walking 45 minutes
Bike riding 30 minutes
Swimming 22 minutes
Running 13 minutes
Sitting on the couch watching TV 3 1/4 hours
Climbing 12 flights of stairs

often don't expect to hear that they need to lose weight. In my experience, patients can and will punish the bearer of this news in a variety of ways, including (but not limited to) describing (in excruciating and time-consuming detail) what they eat, explaining (in excruciating and time-consuming detail) why they can't exercise, crying, or complaining to the hospital administrator. It helps to have a handout and a plan. Our handout includes a BMI chart so the patient can "do the math," rather than take my word for it. It also includes calorie charts for food and exercise (see Tables 2 and 3, above), so that patients can get the message that it is easier not to take in calories than it is to expend them. But it's an uphill battle. I would be a much more popular doctor if I were better at this part of my job, or if I simply didn't take this part of my job so seriously.

It is likely that obesity now kills more Americans than cigarettes do. And, on that point, some parallels might be drawn. Just as we didn't make much progress against cigarette smoking until we stigmatized it, limited it, and taxed it, I doubt we will make much headway against obesity as long as we continue to pretend that it is a harmless lifestyle choice instead of a deadly, chronic, largely self-inflicted disease. ■

References

1. Prospective Studies Collaboration. Body-mass index and cause-specific mortality in 900,000 adults: Collaborative analyses of 57 prospective studies. *Lancet* 2009;373:1083-1096.
2. Flegal KM, et al. Cause-specific excess deaths associated with underweight, overweight, and obesity. *JAMA* 2007;298:2028-2037.
3. Orpana HM, et al. BMI and mortality: Results from a national longitudinal study of Canadian adults. *Obesity (Silver Spring)* 2010;18:214-218.
4. Calle EE, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. *N Engl J Med* 2003;348:1625-1638.
5. Pischon T, et al. General and abdominal adiposity and risk of death in Europe. *N Engl J Med* 2008;359:2105-2120; Erratum published in: *N Engl J Med* 2010;362:2433.
6. International Obesity Task Force. Global prevalence of adult obesity. Available at: www.who.int/databases/documents/GlobalPrevalenceofAdultObesityOctober2009v2.pdf.
7. Ogden CL, et al. Prevalence of overweight and obesity in the United States, 1999-2004. *JAMA* 2006;295:1549-1555.
8. Fruit Lovers, Weight Watchers Has Good News: Oreo Fans, Sorry. *New York Times*, Dec. 4, 2010, p A1.
9. Tsai AG, Wadden TA. Systematic review: An evaluation of major commercial weight loss programs in the United States. *Ann Intern Med* 2005;142:56-66.
10. Panel Votes to Expand Surgery for Less Obese. *New York Times*, Dec. 4, 2010, p B1.

The New Face of Hepatitis A

ABSTRACT & COMMENTARY

By Mary Elina Ferris, MD

Clinical Associate Professor,
University of Southern California

Dr. Ferris reports no financial relationship to this field of study.

Synopsis: Hepatitis A has been greatly reduced in the United States due to widespread vaccination, and most new cases are now the result of international travel.

Source: The evolving epidemiology of hepatitis A in the United States. *Arch Intern Med* 2010;170:1811-1818.

HEPATITIS A CONTINUES TO BE A SIGNIFICANT ILLNESS, WITH an estimated 1.4 million new cases worldwide. In developing countries, children develop immunity after infection, so outbreaks are infrequent. In other countries, where children do not become immune from natural exposure, adult populations are susceptible and outbreaks can occur, including many countries in the European Union.

The U.S. Centers for Disease Control and Prevention (CDC) recruited states covering 30 million persons to participate in the Emerging Infections Program (EIP), which involved molecular testing of hepatitis A virus strains to more thoroughly describe the infections that do occur in the United States. For the years 2005-2007, 1156 cases of hepatitis A were reported, and 49% were from New York City. Of these, 39% were Hispanic. Most cases occurred in urban areas. The most common source of infection was international travel or being exposed to a traveler, with Mexico being the most common associated source. For patients reporting travel as their only known risk factor, 86 of 108 cases were traveling to their county of native birth. One outbreak in Minnesota was associated with a foodborne outbreak, but most others involved international travel as the most likely source. This was confirmed with molecular analysis, which showed that the strains from the travel-related cases were very similar to strains in the countries where the travel occurred.

Before vaccination was available for hepatitis A, only 4% of U.S. cases were associated with international travel; now 46% of cases are travel-related. The national vaccination strategy was expanded to all children age 2 years and older in 1999; by 2003, this resulted in a 76% decline in the incidence of hepatitis A overall, and an 87% decline in incidence among children age 2-18 years. Since 2006, national recommendations for hepatitis A vaccine include all children age 12 months or older in the United States.

■ COMMENTARY

This is a remarkable success story for the reduction of hepatitis A in the United States, from approximately 26,000 or more annual cases before the vaccine to only 600 cases during this study period. The disease in adults can cause major morbidity and even fatal liver failure. An interesting consequence of this success is that the disease now has a different epidemiology, changing from outbreak-associated to mainly sporadic cases associated with international travel.

It's important for clinicians to understand this change in the incidence of hepatitis A, because it means that preventive strategies must target international travelers as well as universal childhood immunization. The most high-risk group is persons returning to their native countries to visit family and friends.¹ Tourists and business

travelers had a lower risk of infection. Ongoing surveillance of hepatitis A continues to be important so that we can understand where and when it occurs, and respond appropriately. ■

References

1. Anderson KL. Hepatitis A: A traveling target. *Arch Intern Med* 2010;170:1818-1819.

Treating Sexual Dysfunction Related to Use of Antidepressants

ABSTRACT & COMMENTARY

By Frank W. Ling, MD

Clinical Professor, Department of Obstetrics and Gynecology, Vanderbilt University, School of Medicine, Nashville

Dr. Ling reports no financial relationship to this field of study.

This article originally appeared in the December 2010 issue of *OB/GYN Clinical Alerts*. At that time it was peer reviewed by Catherine LeClair, MD, Associate Professor, Department of OB/GYN, Oregon Health & Science University, Portland. Dr. LeClair reports no financial relationship to this field of study.

Synopsis: In a prospective, randomized, double-blind, placebo-controlled trial of women taking SRIs, sildenafil treatment resulted in a reduction of sexual side effects.

Source: Nurnberg HG et al. Sildenafil treatment of women with antidepressant-associated sexual dysfunction. *JAMA* 2008;300:395-404.

A STUDY GROUP OF 98 PATIENTS WAS ENROLLED THROUGH seven centers to evaluate the efficacy of sildenafil in the treatment of sexual dysfunction associated with the use of selective and nonselective serotonin reuptake inhibitors (SRIs). The patients had to be previously sexually functioning, premenopausal, and successfully treated for their depression with an SRI, but with sexual dysfunction at the time of enrollment. Several validated scales of sexual functioning were used to assess outcomes with the primary outcome being changes on the Clinical Global Impression sexual function scale (CGI). In the 8-week parallel group study, patients took either placebo or sildenafil (50-100 mg flexible dosing schedule) prior to activity. The CGI score of women treated with sildenafil was 1.9 (95% confidence interval [CI], 1.6-2.3), while those

taking placebo scored on average 1.1 (95% CI, 0.8-1.5). Hormone levels were comparable and the rate of depression remission was also the same.

■ COMMENTARY

How often has a patient asked you, “Why isn’t there a Viagra for women?” Well, there is ... sort of. There was a minor blip on the radar screen of the medical news when this first came out in 2008, but the enthusiasm has somewhat died. The antidepressant-associated sexual dysfunction that we all encounter in our daily practices remains a challenge looking for an effective solution. As an editorial aside, I am particularly sensitive to this because of my skewed patient population that is heavy on chronic pelvic pain, antidepressant use, and sexual dysfunction. Particularly disconcerting is the repeated scenario in which patients prematurely discontinue their antidepressant therapy because of the sexual side effects. What are we to do?

We know that the phenomenon is common, i.e., the literature tells us that anywhere from 30% to 70% of patients on selective and nonselective serotonin reuptake inhibitors develop symptoms such as decrease in libido, vaginal lubrication, and sensitivity. In addition, women are also troubled by orgasmic dysfunction, dyspareunia, reduced sexual activity, and reduced satisfaction.

The relevance of the problem and the data in this article should be placed in proper perspective within the landscape of sexual dysfunction, which currently consists of four categories: sexual desire disorders (including hypoactive desire and aversion), sexual arousal disorders, sexual orgasmic disorders, and sexual pain disorders (dyspareunia and vaginismus). Whereas sildenafil is FDA-approved for arousal disorders in men, SRI-induced dysfunction is typically of the desire or orgasm type. To complicate the picture further, desire dysfunction (loss of libido) is the most common type of sexual dysfunction in females. If sildenafil works in women as it does in men, it should not directly affect libido, but should improve blood flow to the pelvic region. In men, this results in erection whereas in women, it would lead to more vasocongestion and vaginal lubrication, thereby simulating the normal physiologic response of arousal and reducing dyspareunia.

Even though the literature is not totally consistent in identifying a benefit for the use of sildenafil, it should be noted that this group of patients does show potential efficacy. Since we all see patients that might benefit from its use, knowing that there might be something available at least gives us another option to consider. As with men, the medication is used prior to sexual activity. This study started with 50 mg and allowed the patient to take up to 100 mg. In other studies involving male subjects, doses

of up to 200 mg have been reported. When I offer this choice to patients, I typically start with the lowest dose, 25 mg, then increase from there.

Patient education is critical when considering applying these data. First, the clinician should recognize that depression itself can have a deleterious effect on sexual functioning. Also, an antidepressant, be it SRI or not, has the potential for adversely affecting libido and other aspects of sexual functioning. Sometimes, it becomes the proverbial “Which came first, the chicken or the egg?” quandary, trying to sort out what whether the sexual dysfunction antedated the use of the antidepressant or, more specifically, the SRI. The patient should be told specifically that the goal is not to increase libido directly. In men, it does not increase libido, but does increase blood flow to the penis, thereby generating the erection that allows the man to be sexually functional.

Other small series or case reports have suggested other approaches to these complaints, none of which has shown more than limited efficacy. The concept of a “drug holiday” in which the patient takes the SRI only on weekdays in order to be more sexually functional on the weekends has now been marginalized because of the tendency of the patient to be less compliant with taking the medication on a regular basis. Adding a non-SRI medication such as bupropion has shown limited success. Reports on yohimbine, urecholine, and periactin have been published. Any of you out there who has tried to deal with this problem has certainly found it frustrating and difficult.

Perhaps this report might allow some of us to step out and try it more often. We will continue to be asked by patients, so we might as well be open to new possibilities. As products are tested and new reports come out, we’ll be watching. The testosterone patch has still not gotten here despite much anticipation. We know that women’s

To reproduce any part of this newsletter for promotional purposes, please contact:

Stephen Vance

Phone: (800) 688-2421, ext. 5511

Email: stephen.vance@ahcmedia.com

To obtain information and pricing on group discounts, multiple copies, site-licenses, or electronic distribution please contact:

Tria Kreutzer

Phone: (800) 688-2421, ext. 5482

Email: tria.kreutzer@ahcmedia.com

To reproduce any part of AHC newsletters for educational purposes, please contact:

The Copyright Clearance Center for permission

Email: info@copyright.com

Phone: (978) 750-8400

sexual functioning is a different issue when compared to men. As I tell my patients, “Men use sex as stress relief, while women need to have stress relieved before they can have sex.” Yes, it’s different, not as simple, but certainly worth our continued efforts. ■

Pharmacology Update

Dextromethorphan Hydrobromide and Quinidine Sulfate Tablets (Nuedexta™)

By William T. Elliott, MD, FACP, and James Chan, PharmD, PhD

Dr. Elliott is Chair, Formulary Committee, Northern California Kaiser Permanente; and Assistant Professor of Medicine, University of California, San Francisco. Dr. Chan is Pharmacy Quality and Outcomes Manager, Kaiser Permanente, Oakland, CA.

Drs. Elliott and Chan report no financial relationship to this field of study.

THE FDA HAS APPROVED THE FIRST TREATMENT FOR PSEUDO-bulbar affect (PBA). This condition is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying and is secondary to certain underlying neurologic diseases or injuries. This new combination product contains a N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 agonist, dextromethorphan, and a CYP 450 2D6 inhibitor, quinidine. The product will be marketed by Avanir Pharmaceuticals, Inc., as Nuedexta™ in the first quarter of 2011.

Indications

Dextromethorphan (DEX)/quinidine (QUIN) is indicated for the treatment of pseudobulbar affect.¹

Dosage

The recommended dose is 1 capsule daily for 7 days and then 1 capsule every 12 hours.¹

The product is available as capsules, each containing DEX 20 mg and QUIN 10 mg.

Potential Advantages

DEX/QUIN reduced laughing and crying episodes compared to placebo in patients with amyotrophic lateral sclerosis and multiple sclerosis.¹

Potential Disadvantages

DEX/QUIN may cause dose-dependent QTc prolongation. It is contraindicated in patients with prolonged QT interval, congenital long QT syndrome, history suggestive of torsades de pointes, heart failure, or risk of complete atrioventricular block (implanted pacemaker the exception).¹ Concomitant use of drugs that prolonged QT interval and are metabolized by CYP 2D6 is contraindicated. Common adverse events, compared to placebo, include diarrhea (13% vs 6%), dizziness (10% vs 5%), cough (5% vs 2%), vomiting (5% vs 1%), asthenia (5% vs 2%), peripheral edema (5% vs 1%), urinary tract infection (4% vs 1%), influenza (4% vs 1%), increased gamma-glutamyltransferase (3% vs 0%), and flatulence (3% vs 1%). Thrombocytopenia and lupus-like syndrome have been associated with quinidine.

Comments

Dextromethorphan is a low-affinity, noncompetitive NMDA-receptor antagonist and sigma-1 receptor agonist. Quinidine, a potent CYP P450 2D6 inhibitor, blocks first-pass metabolism resulting in improved systemic exposure of dextromethorphan. The exact mechanism of action in treating pseudobulbar affect is not known. The efficacy was evaluated in a 12-week, randomized, double-blind, placebo-controlled study in patients with amyotrophic lateral sclerosis or multiple sclerosis.^{1,2} The study randomized patients to DEX/QUIN 30 mg/10 mg (n = 110), DEX/QUIN 20 mg/10 mg (n = 107), or placebo (n = 109). The primary endpoint was patient’s change from baseline in the number of PBA episodes of laughing and/or crying per day as recorded in the patient’s diary. A secondary endpoint was the patient’s change from baseline on Center for Neurologic Studies Lability Scale (CNS-LS). This is a 7-item self-assessment of PBA severity. With no clear clinical advantage with the higher dose, only the 20 mg/10 mg was approved by the FDA. DEX/QUIN 20 mg/10 mg showed a 49% reduction compared to placebo ($P < 0.001$). The 12-week mean change in daily episodes was -3.9 compared to -3.0 for placebo ($P = 0.0099$). There was a significant reduction from baseline CNS-LS compared to placebo (8.2 vs 5.7; $P = 0.011$). Remission was reported in approximately 50% of patients treated with DEX/QUIN compared to approximately 30% for placebo.² Remission was defined as absence of episodes throughout the final two weeks of the 12-week study. Dizziness and diarrhea were more common with DEX/QUIN compared to placebo (10.3% vs 5.5% and 13.1% vs 6.4%, respectively).²

Clinical Implications

Pseudobulbar affect is a disorder of emotional expression characterized by uncontrollable outbursts of laughing

and/or crying.³ This disorder appears to occur in the setting of neurological diseases such as amyotrophic lateral sclerosis and multiple sclerosis. Current therapies include tricyclic antidepressants and selective serotonin reuptake inhibitors and may be considered in patients with depression.³ DEX/QUIN is the first FDA-approved treatment for this condition. Whether the efficacy of this combination of drugs can be generalized to other causes of pseudobulbar affect not related to ALS or MS is not known. ■

References

1. Nuedexta Prescribing Information. Aliso Viejo, CA: Avanir Pharmaceuticals, Inc.; October 2010.
2. Pioro EP, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. *Ann Neurol* 2010;68:693-702.
3. Rosen H. Dextromethorphan/quinidine sulfate for pseudobulbar affect. *Drugs Today (Barc)* 2008;44:661-668.

Brief Report

'Weekend Effect' and Stroke

By Matthew E. Fink, MD

Interim Chair and Neurologist-in-Chief, Director, Division of Stroke & Critical Care Neurology, Weill Cornell Medical College and New York Presbyterian Hospital

Dr. Fink reports no financial relationship to this field of study.

This article originally appeared in the November issue of *Neurology Alert*. At that time it was peer reviewed by M. Flint Beal, MD, Anne Parrish Titzel Professor, Department of Neurology and Neuroscience, Weill Cornell Medical Center. Dr. Beal reports no financial relationship to this field of study.

Source: Hoh BL, et al. Effect of weekend compared with weekday stroke admission on thrombolytic use, in-hospital mortality, discharge disposition, hospital charges, and length of stay in the Nationwide Inpatient Sample Database, 2002 to 2007. *Stroke* 2010; 41:2323-2338.

ASTROKE "WEEKEND EFFECT" ON MORTALITY HAS BEEN noted in studies reported from countries other than the United States. The authors reviewed the U.S. National Inpatient Sample database from 2002 to 2007 for all emergency room admissions with ICD-9 classifications of acute ischemic stroke, to compare weekend vs. weekday stroke admission incidence of thrombolytic use, in-hospital mortality, discharge disposition, hospital charges, and length of stay. Adjustments were made to correct for differences in age, gender, season, median income, payer

source, comorbidities, hospital location, teaching status, and hospital size.

There were 599,087 emergency room admissions for ischemic stroke: 439,181 weekday admissions and 159,906 weekend admissions. Compared to weekday admissions, patients with acute ischemic stroke admitted on weekends were slightly more likely to receive thrombolytics (OR = 1.114; $P = 0.003$), incur higher total hospital charges (effect ratio = 1.001; $P < 0.001$), and have slightly longer lengths of stay (effect ratio = 1.021; $P < 0.001$). There was no difference in hospital mortality or disposition at time of discharge. ■

CME Questions

65. Obesity:

- a. kills.
- b. is defined as a BMI > 35 kg/m².
- c. is decreasing in prevalence in the United States.
- d. is safer for younger people than older people.

66. Which of the following groups in the United States is at highest risk for new cases of hepatitis A?

- a. Restaurant workers
- b. Business travelers to developing countries
- c. Tourists traveling internationally
- d. Travelers returning internationally to native countries
- e. Children traveling internationally

67. Which of the following types of sexual dysfunction is most common in women?

- a. Sexual arousal disorders
- b. Sexual desire disorders
- c. Sexual orgasmic disorders
- d. Sexual pain disorders

Answers: 65. a, 66. d, 67. b.

CME Objectives

Upon completion of this educational activity, participants should be able to:

- describe new findings in the differential diagnosis and treatment of various diseases;
- describe the advantages, disadvantages and controversies surrounding the latest advances in the diagnosis and treatment of disease;
- identify cost-effective treatment regimens;
- explain the advantages and disadvantages of new disease screening procedures.

By Louis Kuritzky, MD, Clinical Assistant Professor, University of Florida, Gainesville
Dr. Kuritzky is a consultant for Abbott, AstraZeneca, Boehringer Ingelheim, Daiichi,
Sankyo, Forest Pharmaceuticals, Lilly, Novo Nordisk, Takeda.

Coenzyme Q10 for Peyronie's disease

Source: Safarinejad MR. Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie's disease. *Int J Impot Res* 2010;22:298-309.

PEYRONIE'S DISEASE IS AN UNCOMMON PENILE fibrotic disorder that most commonly affects young and middle-aged men. It is characterized by pain, deformity, or decreased capacity for intromission as a result of penile angulation. In contrast to chordee, the congenital abnormality in which ventral penile tissue defects prevent full expansion of the underside of the penis, resulting in a downward curvature upon erection, Peyronie's disease is an acquired fibrosis of the penis, which results in thickened penile plaques that prevent full erection. In whatever area of the penis such fibrotic plaques occur, that area will be unable to achieve full dilation and erection, resulting in angulation of the penis. There is no uniformly effective treatment for Peyronie's disease, although surgical correction is often effective.

Fibrotic plaque analysis in Peyronie's disease has demonstrated early oxidative inflammation, followed by creation of fibrotic scar. Since coenzyme Q10 has been shown to have antioxidant capacity, a clinical trial of its efficacy in early Peyronie's was intuitively appealing.

Men with early Peyronie's disease (n = 186) were randomized to coenzyme Q10 300 mg/day or placebo for 24 weeks. At trial end, there was a statistically significant reduction in plaque size, penile curvature, and improvement in sexual function in the active treatment group. Because coenzyme Q10 is a very well tolerated intervention with no known serious adverse effects (there were no reported drug-related adverse events or discontinuations), it offers a promising

alternative for persons with Peyronie's disease. ■

Impact of using A1c to diagnose pre-diabetes

Source: Mann DM, et al. Impact of A1c screening criterion on the diagnosis of pre-diabetes among U.S. adults. *Diabetes Care* 2010;33:2190-2195.

THE DRAMATIC INCREASE IN TYPE 2 DIABETES (DM2) seen in the last decade is predictably going to become even more evident: Although 24 million Americans currently have DM2, more than twice as many have pre-diabetes (p-DM2). Historically, persons with p-DM2 who are untreated progress to frank DM2 at a rate of 7%-10% per year.

Until 2010, p-DM2 was diagnosed based upon the presence of either impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or both. Since 2010, the ADA has indicated that an A1c of 5.7%-6.4% qualifies as p-DM2. This tool has been welcomed by the primary care community because it does not require fasting, and can be obtained during any routine office visit. The limitation of A1c, however, is that it does not necessarily capture all the persons who would have been identified had either a fasting blood glucose or postprandial glucose (or both) been obtained; data from NHANES indicate that a substantial number of persons with IFG will not have an abnormal A1c, and vice versa. For instance, of 51.7 million NHANES subjects with IFG, only 23 million have an A1c that meets p-DM2 criteria.

All of the diagnostic markers for p-DM2 are used in an effort to identify the pathophysiologic derangements at a point in time where intervention might change disease progression. IFG, IGT, and A1c identify overlapping, but not identical, populations. Because clinicians will commonly have access to fasting

glucose levels obtained concomitantly with other labs (e.g., CMP), it appears that few cases of p-DM2 will be missed by utilizing an A1c measurement. ■

Should tiotropium be a maintenance asthma medication?

Source: Peters SP, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. *N Engl J Med* 2010;363:1715-1726.

TRADITIONAL MAINTENANCE PHARMACOTHERAPY for persistent asthma includes inhaled corticosteroids (ICS), leukotriene modulators, and—when used concomitantly with ICS—long-acting beta agonists (LABA). Except for the acute care setting, anticholinergic treatment, like tiotropium (TIO) has been generally thought of as a treatment for COPD rather than asthma.

Peters et al performed a double-blind, crossover trial in asthmatics (n = 210) who were poorly controlled on ICS alone. As add-on treatment, patients were randomized to tiotropium (ICS + TIO), the long-acting beta agonist salmeterol (ICS + LABA), or a doubling of ICS (ICS + ICS).

ICS + TIO was found to be superior to ICS + ICS for morning peak expiratory flow (the primary endpoint of the trial). ICS + TIO was demonstrated to be non-inferior to ICS + LABA for morning peak expiratory flow, prebronchodilator FEV1, and proportion of asthma-controlled days (the secondary endpoint of the trial). These results support the consideration of TIO as a maintenance medication for asthma when used in conjunction with ICS. Because the study duration was brief (14 weeks), the durability of anticholinergic treatment for asthma—for instance, is TIO useful in preventing asthma exacerbations?—remains to be determined. ■

INTERNAL MEDICINE ALERT®

A twice-monthly update of developments in internal and family medicine

Cumulative Index Volume 32, Numbers 1-24, Pages 1-192 January 15, 2010–December 29, 2010

-
- A**
- actinic keratoses**
 - imiquimod, 10:80
 - adverse effects**
 - under-detection, 13:103
 - alcohol**
 - cardiovascular disease, 10:73
 - allopurinol**
 - angina, 15:119
 - Alzheimer's disease**
 - dietary pattern, 18:141
 - angina**
 - allopurinol, 15:119
 - angiotensin-receptor blocker**
 - congestive heart failure, 2:11
 - antibiotics**
 - urinary tract infection, 6:41
 - anticonvulsants**
 - suicide risk, 12:96
 - antidepressants**
 - depression severity, 3:17
 - sexual dysfunction, 24:188
 - aortic valve stenosis**
 - valve replacement, 5:36
 - aspirin**
 - diabetes, 4:32
 - hypertension, 21:167
 - low-dose, 2:11
 - peptic ulcer disease, 2:11
 - assessment**
 - family history, 3:19
 - asthma**
 - obesity, 16:128
 - tiotropium, 24:192
 - atrial fibrillation**
 - dabigatran, 21:167
 - heart rate control, 9:68
 - warfarin, 21:167
- B**
- bariatric surgery**
 - diabetes, 5:39
 - exercise**, 9:71
 - risks**, 18:144
 - beta-blocker**
 - COPD, 16:123
 - beta-cell function**
 - diabetes, 8:64
 - bleeding risk**
 - warfarin therapy, 23:183
 - BMI**
 - cardiovascular risk, 7:51
 - mortality, 24:185
 - breast cancer**
 - mammography, 20:155
- C**
- calcium supplementation**
 - myocardial infarction, 19:148
 - cancer risk**
 - fruit and vegetable intake, 9:66
 - cardiovascular disease**
 - alcohol, 10:73
 - BMI, 7:51
 - clopidogrel, 23:183
 - coronary calcium score, 11:87, 15:113
 - fibrates, 14:108, 15:119
 - LDL reduction, 1:7
 - metabolic syndrome, 7:51
 - omega-3 fatty acids, 22:172
 - pulmonary function, 22:170
 - risk assessment, 5:33
 - vital exhaustion, 17:121
 - C. difficile***
 - COPD exacerbation, 12:89
 - celecoxib**
 - NSAID + PPI, 17:135
 - celiac disease**
 - testing, 13:99
 - cervical strain**
 - cyclobenzaprine, 7:49
 - ibuprofen, 7:49
 - chest CT angiography**
 - pulmonary embolism, 3:20
 - chest pain**
 - work-up, 6:43
 - childhood cancer**
 - lifetime follow-up, 22:169
 - chronic kidney disease**
 - dialysis, 19:151
 - estimated GFR, 12:93
 - proteinuria, 6:48
 - cirrhosis**
 - weight, 10:74
 - clopidogrel**
 - cardiovascular outcomes, 23:183
 - cluster headache**
 - oxygen therapy, 2:16
 - P450 system, 23:183
 - coenzyme Q10**
 - Peyronie's disease, 24:192
 - cognitive therapy**
 - depression, 4:32
 - colchicine**
 - gout, 14:105
 - colon cancer**
 - screening, 22:176
 - congestive heart failure**
 - angiotensin-receptor blocker, 2:11
 - constipation**
 - skim milk, 21:161
 - COPD**
 - beta-blockers, 16:123
 - C. difficile*, 12:89
 - exacerbations, 6:48, 11:87, 12:89, 15:115, 18:139
 - corticosteroids, 6:48; 15:115
 - ipratropium, 5:39
 - osteoporosis, 3:23
 - coronary artery disease**
 - coronary angiography, 7:55
 - QRS duration, 4:27
 - coronary calcium scores**
 - cardiovascular risk, 11:87, 15:113
 - coronary heart disease**
 - sleep apnea, 16:121

corticosteroids
 COPD exacerbations, 6:48, 15:115

cough
 obstructive sleep apnea, 5:35
 pertussis, 20:157

cyclobenzaprine
 acute cervical strain, 7:49

D

dabigatran
 atrial fibrillation, 21:167

dairy intake
 oxidative stress, 8:61

deep vein thrombosis
 screening, 10:76

dementia
 aggressive behavior, 21:167
 driving privileges, 12:91
 feeding tube insertion, 8:58
Ginkgo biloba, 4:32
 lying obliquely, 2:9

depression
 cognitive therapy, 4:32
 severity, 3:17
 sleep disturbance, 10:80

diabetes
 aspirin, 4:32
 bariatric surgery, 5:39
 beta-cell function, 8:64
 exenatide, 14:112, 20:160
 HbA1c, 21:163, 24:192
 hypertension control, 13:103
 lifestyle, 1:7
 metformin, 1:7, 3:23, 8:64, 12:96;
 18:144
 pioglitazone, 20:160
 rosiglitazone, 18:144
 screening frequency, 22:176
 sexual dysfunction, 14:112
 sitagliptin, 20:160
 statins, 7:55

diabetic peripheral neuropathy
 monofilament testing, 11:83

dialysis
 chronic kidney disease, 19:151

dietary sugars
 lipids, 14:112

dizziness
 elderly, 18:137

drug use
 screening, 17:129

dutasteride
 male pattern baldness, 17:135
 prostate cancer risk, 9:71

dyslipidemia
 thyroid hormone analogue, 7:55

E

elderly
 chronic kidney disease, 12:93
 dizziness, 18:137
 falls, 1:7

exenatide
 diabetes, 14:112

exercise
 bariatric surgery, 9:71
 weight, 10:77, 14:106

F

falls
 elderly, 1:7
 hip fracture, 14:109
 physical therapy, 14:109
 vitamin D, 13:100, 14:109

family history
 assessment, 3:19

fatigue
 symptom, 1:3

feeding tube insertion
 dementia, 8:58

fibrates
 cardiovascular disease, 14:108,
 15:119

fibromyalgia
 tai chi, 19:151

fruit and vegetable intake
 cancer risk, 9:66

G

GI bleeding
 NSAIDs, 15:115

Ginkgo biloba
 dementia, 4:32

glucosamine
 low back pain, 15:119

glycemic control
 non-alcoholic steatohepatitis, 6:48

glycemic index
 myocardial infarction, 17:132

gout
 colchicine, 14:105
 diagnosis, 16:124

guidelines
 cardiovascular risk assessment, 5:33

H

HbA1c levels
 diagnosing prediabetes, 24:192
 racial differences, 21:163

headache, acute
 subarachnoid hemorrhage, 23:177

hearing loss
 adolescents, 20:160

heart disease
 salt intake, 1:1

heart failure
 iron, 3:23
 sleep apnea, 16:121

hemiarthroplasty
 home care, 19:147

hepatitis A
 vaccination strategy, 24:187

hernia
 repair methodology, 20:160

hip fracture
 falls, 14:109
 osteoporosis, 11:84
 physical therapy, 14:109

hypercholesterolemia
 early intervention, 20:153

hypertension
 aspirin, 21:167
 carvedilol + lisinopril, 22:176
 diabetes, 13:103
 home monitoring, 12:96
 intensive control, 13:103
 salt intake, 23:183
 systolic variability, 10:80

I

ibuprofen
 acute cervical strain, 7:49

imiquimod
 actinic keratoses, 10:80

immunization
 adults, 4:28

incretins
 insulin, 17:135

insomnia
 mortality, 18:138

insulin
 incretins, 17:135

ipratropium
 COPD, 5:39

iron
 heart failure, 3:23

L

LDL reduction
 cardiovascular disease, 1:7
 statins, 19:145

lead poisoning
 adults, 2:11

Lemierre's syndrome
 pharyngitis, 1:4

lifestyle
 diabetes, 1:7

lipids
 dietary sugars, 14:112

low back pain
 best practices, 7:50
 glucosamine, 15:119

- lung function**
 - smoke exposure, 6:44
- M**
- male pattern baldness**
 - dutasteride, 17:135
- mammography**
 - screening, 20:155
- measles/mumps/rubella vaccine**
 - plantar warts, 16:128
- metabolic syndrome**
 - cardiovascular risk, 7:51
- metformin**
 - diabetes, 1:7, 8:64, 12:96, 18:144
 - exenatide, 14:112
 - prediabetes, 3:23
 - rosiglitazone, 14:112
 - vitamin B12, 13:97
- milk, skim**
 - constipation, 21:161
- monofilament testing**
 - diabetic peripheral neuropathy, 11:83
- mortality**
 - BMI, 24:185
 - insomnia, 18:138
 - Parkinson's disease, 23:180
- muscle cramps**
 - quinine, 8:57
- myocardial infarction**
 - calcium supplementation, 19:148
 - low glycemic index diet, 17:132
- N**
- neurological examination**
 - lying obliquely, 2:9
- non-alcoholic steatohepatitis**
 - glycemic control, 6:48
 - pioglitazone, 11:87
 - vitamin E, 11:87
- NSAIDs**
 - GI bleeding, 15:115
 - vs celecoxib, 17:135
- O**
- obesity**
 - asthma, 16:128
- omega-3 fatty acids**
 - cardiovascular disease, 22:172
- onychomycosis**
 - long-term follow-up, 8:64
- osteoporosis**
 - COPD, 3:23
 - hip fracture, 11:84
 - proton pump inhibitor, 11:81
- oxidative stress**
 - dairy intake, 8:61
- oxygen therapy**
 - cluster headache, 2:16
- P**
- Parkinson's disease**
 - mortality risk, 23:180
- peptic ulcer disease**
 - low-dose aspirin, 2:11
- pertussis**
 - persistent cough, 20:157
 - prevention, 21:163
- Peyronie's disease**
 - coenzyme Q10, 24:192
- pharyngitis**
 - Lemierre's syndrome, 1:4
- photoaging**
 - vitamins, 19:151
- physical therapy**
 - falls, 14:109
 - hip fracture, 14:109
- pioglitazone**
 - diabetes, 20:160
 - non-alcoholic steatohepatitis, 11:87
- plantar warts**
 - measles/mumps/rubella vaccine, 16:128
- pressure ulcers**
 - vitamin C, 9:71
 - zinc, 9:71
- prostate cancer**
 - active surveillance, 23:179
 - dutasteride, 9:71
- proteinuria**
 - kidney function, 6:48
- proton pump inhibitor**
 - fracture risk, 11:81
 - NSAIDs, 17:135
- pulmonary embolism**
 - chest CT angiography, 3:20
- pulmonary function**
 - cardiovascular death risk, 22:170
- Q**
- quinine**
 - muscle cramps, 8:57
- QRS duration**
 - coronary artery disease, 4:27
- R**
- retail clinics**
 - patient preference, 8:60
- rosiglitazone**
 - diabetes, 14:112, 18:144
- S**
- salt intake**
 - heart disease, 1:1
 - hypertension, 23:183
 - stroke, 1:1
- sexual dysfunction**
 - antidepressants, 24:188
 - diabetes, 14:112
- sitagliptin**
 - diabetes, 20:160
- sleep apnea**
 - coronary heart disease, 16:121
 - chronic cough, 5:35
 - heart failure, 16:121
 - home-based testing, 18:144
 - weight loss, 4:25
- sleep disturbance**
 - depression, 10:80
- smoke exposure**
 - risk of decreased lung function, 6:44
- statins**
 - diabetes, 7:55
 - LDL levels, 19:145
- stroke**
 - admission pattern, 24:191
 - salt intake, 1:1
- subarachnoid hemorrhage**
 - acute headache, 23:177
- suicide risk**
 - anticonvulsants, 12:96
- T**
- tai chi**
 - fibromyalgia, 19:151
- testosterone replacement**
 - safety, 16:128
- thyroid hormone analogue**
 - dyslipidemia, 7:55
- tiotropium**
 - asthma, 24:192
- U**
- urinary tract infection**
 - antibiotic use, 6:41
- V**
- vaccinations**
 - hepatitis A, 24:187
- valve replacement**
 - aortic stenosis, 5:36
- venous thromboembolism**
 - risk of complication, 9:65
 - screening, 10:76
- vital exhaustion**
 - cardiovascular disease, 17:121
- vitamin B12**
 - metformin, 13:97
- vitamin C**
 - pressure ulcers, 9:71
- vitamin D**
 - falls, 13:100
 - hip fracture, 14:109
 - source, 13:103
- vitamin E**
 - non-alcoholic steatohepatitis, 11:87

vitamins

photoaging, 19:151

W**warfarin**

atrial fibrillation, 21:167
bleeding risk, 23:183

weight

cirrhosis, 10:74
exercise, 10:77, 14:106
obstructive sleep apnea, 4:25

Z**zinc**

pressure ulcers, 9:71

Pharmacology Update

Capsaicin Patch 8% (Qutenza™), 1:5
Tranexamic Acid Tablets (Lysteda™),
2:14
Ecallantide Injection (Kalbitor®), 3:21
Tocilizumab Injection (Actemra®), 4:30
Liraglutide Injection (Victoza®), 5:37
Dalfampridine Extended Release Tablets
(Ampyra™), 6:46
Hydromorphone HCl Extended-release
Tablets (Exalgo™) CII, 7:52
Aztreonam for Inhalation (Cayston®),
8:62
Rifaximin Tablets (Xifaxan®), 9:69
Miconazole Buccal Tablets (Oravig™),
10:78

Sipuleucel-T Suspension for Intravenous
Infusion (Provenge®), 11:85
Naproxen and Esomeprazole Delayed-
release Tablets (Vimovo®), 12:94
Ketorolac Tromethamine Nasal Spray
(Sprix™), 13:101
Everolimus Tablets (Zortress®), 14:110
Denosumab Injection (Prolia™), 15:117
Dutasteride and Tamsulosin HCl
Capsules (Jalyn™), 16:126
Olmesartan, Amlodipine,
Hydrochlorothiazide Tablets
(Tribenzor™), 17:133
Mometasone Furoate and Formoterol
Furmarate Inhalation Aerosol
(Dulera®), 18:142
Ulipristal Acetate Tablets (Ella™),
19:149
Pegloticase Injection (Krystexxa™),
20:158
Fingolimod Capsules (Gilenya™),
21:165
Dabigatran Etxilate Mesylate Capsules
(Pradaxa®), 22:174
Drospirone/Ethinyl Estradiol/
Levomefolate Calcium Tablets
(Beyaz™), 23:181
Dextromethorphan Hydrobromide and
Quinidine Sulfate Tablets
(Nuedexta™), 24:190

ECG Review

Periodic Weakness? 1:8
A Funny Feeling in My Chest, 3:24
What Is the Frequency? 5:40
Some Pulmonary Diagnoses, 7:56
A 54-Year-Old Man with Chest Pain,
9:71
RBBB Plus? 11:88
Is There a Grouping? 13:104
Paced Abnormality? 15:120
An Interpolated Tracing, 17:136
An Asymptomatic 87-year-old Woman,
19:152
P Pulmonale? 21:168
A Burst of VT? 23:184



INTERNAL MEDICINE ALERT®

A twice-monthly update of developments in internal and family medicine

IMA122910TM

PLEASE NOTE: If your correct name and address do not appear below, please complete the section at right.

Please make label address corrections here or PRINT address information to receive a credit letter.

Account #: _____
 Name: _____
 Company: _____
 Address: _____
 City: _____
 State: _____
 Zip: _____
 Fax: _____
 Phone: _____
 E-mail: _____

CME Evaluation

Please take a moment to answer the following questions to let us know your thoughts on the CME program. Fill in the appropriate space and return this page in the envelope provided. **You must return this evaluation to receive your credit letter.**
 Thank you.

CORRECT INCORRECT

1. If you are claiming physician credits, please indicate the appropriate credential: MD DO Other _____

	Strongly Disagree	Disagree	Slightly Disagree	Slightly Agree	Agree	Strongly Agree
After completion of this program, I am able to:						
2. Describe new findings in the differential diagnosis and treatment of various diseases.	<input type="radio"/>					
3. Describe the advantages, disadvantages, and controversies surrounding the latest advances in the diagnosis and treatment of disease.	<input type="radio"/>					
4. Identify cost-effective treatment regimens.	<input type="radio"/>					
5. Explain the advantages and disadvantages of new disease screening procedures.	<input type="radio"/>					
6. The test questions were clear and appropriate.	<input type="radio"/>					
7. I am satisfied with customer service for the CME program.	<input type="radio"/>					
8. I detected no commercial bias in this activity.	<input type="radio"/>					
9. This activity reaffirmed my clinical practice.	<input type="radio"/>					
10. This activity has changed my clinical practice. If so, how?	<input type="radio"/>					

11. How many minutes do you estimate it took you to complete this activity? Please include time for reading, reviewing, answering the questions, and comparing your answers with the correct ones listed. _____ minutes.

12. Do you have any general comments about the effectiveness of this CME program?

I have completed the requirements for this activity.

Name (printed) _____

Signature _____